JP2005505270A5 - - Google Patents

Download PDF

Info

Publication number
JP2005505270A5
JP2005505270A5 JP2003526345A JP2003526345A JP2005505270A5 JP 2005505270 A5 JP2005505270 A5 JP 2005505270A5 JP 2003526345 A JP2003526345 A JP 2003526345A JP 2003526345 A JP2003526345 A JP 2003526345A JP 2005505270 A5 JP2005505270 A5 JP 2005505270A5
Authority
JP
Japan
Prior art keywords
antigen
cell
interleukin
cells
dendritic cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003526345A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005505270A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/028620 external-priority patent/WO2003022215A2/en
Publication of JP2005505270A publication Critical patent/JP2005505270A/ja
Publication of JP2005505270A5 publication Critical patent/JP2005505270A5/ja
Pending legal-status Critical Current

Links

JP2003526345A 2001-09-06 2002-09-06 単球性樹状細胞およびt細胞にth−1応答をプライミングするための組成物および方法 Pending JP2005505270A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31759201P 2001-09-06 2001-09-06
PCT/US2002/028620 WO2003022215A2 (en) 2001-09-06 2002-09-06 Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011148711A Division JP5777956B2 (ja) 2001-09-06 2011-07-04 単球性樹状細胞およびt細胞にth−1応答をプライミングするための組成物および方法

Publications (2)

Publication Number Publication Date
JP2005505270A JP2005505270A (ja) 2005-02-24
JP2005505270A5 true JP2005505270A5 (enExample) 2005-12-08

Family

ID=32654226

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2003526345A Pending JP2005505270A (ja) 2001-09-06 2002-09-06 単球性樹状細胞およびt細胞にth−1応答をプライミングするための組成物および方法
JP2011148711A Expired - Fee Related JP5777956B2 (ja) 2001-09-06 2011-07-04 単球性樹状細胞およびt細胞にth−1応答をプライミングするための組成物および方法
JP2015040165A Expired - Fee Related JP6114768B2 (ja) 2001-09-06 2015-03-02 単球性樹状細胞およびt細胞にth−1応答をプライミングするための組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011148711A Expired - Fee Related JP5777956B2 (ja) 2001-09-06 2011-07-04 単球性樹状細胞およびt細胞にth−1応答をプライミングするための組成物および方法
JP2015040165A Expired - Fee Related JP6114768B2 (ja) 2001-09-06 2015-03-02 単球性樹状細胞およびt細胞にth−1応答をプライミングするための組成物および方法

Country Status (17)

Country Link
US (2) US20050059151A1 (enExample)
EP (3) EP1441591B1 (enExample)
JP (3) JP2005505270A (enExample)
KR (3) KR20110081341A (enExample)
CN (2) CN1636229B (enExample)
AU (1) AU2008221592B2 (enExample)
BR (1) BRPI0212545B8 (enExample)
CA (1) CA2459713C (enExample)
DK (2) DK1441591T3 (enExample)
ES (2) ES2766299T3 (enExample)
IL (3) IL160720A0 (enExample)
MX (1) MXPA04002147A (enExample)
NO (2) NO338147B1 (enExample)
NZ (1) NZ531530A (enExample)
PL (1) PL372098A1 (enExample)
PT (2) PT2322603T (enExample)
WO (1) WO2003022215A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT412145B (de) * 2002-09-13 2004-10-25 Forsch Krebskranke Kinder Verfahren zur herstellung eines zellulären immuntherapeutikums auf basis von il-12-freisetzenden dendritischen zellen
US20040057935A1 (en) * 2002-09-20 2004-03-25 Cedars-Sinai Medical Center Intratumoral delivery of dendritic cells
CN102600461B (zh) * 2002-12-06 2017-07-14 西北生物治疗药物公司 给予体外部分成熟的树突细胞治疗肿瘤
ATE420946T1 (de) * 2003-02-27 2009-01-15 Northwest Biotherapeutics Inc Erzeugung dendritischer zellen aus monozytischen dendritischen vorläuferzellen mit gm-csf ohne anwesenheit zusätzlicher zytokine
EP1484064A1 (en) 2003-06-04 2004-12-08 Gesellschaft für Biotechnologische Forschung Therapeutical composition containing dentritic cells and use thereof
WO2005037995A2 (en) * 2003-10-06 2005-04-28 Cedars-Sinai Medical Center Use of cox-2 inhibitor to prevent t-cell anergy induced by dendritic cell therapy
EP1676132B1 (en) * 2003-10-21 2014-01-22 Cedars-Sinai Medical Center Combination of chemotherapy and administration of glioma-antigen-pulsed dendritic cells in the treatment of glioma
KR101279748B1 (ko) * 2003-11-04 2013-07-04 가부시키가이샤 디나벡크 겐큐쇼 유전자 도입된 수상세포의 제조방법
EP1775343A4 (en) 2004-06-24 2007-11-14 Dnavec Research Inc ANTITUM-AGENT WITH DENDRITIC CELL WITH THE TRANSFECTED RNA VIRUS
EP1957634A4 (en) * 2005-12-08 2010-01-27 Northwest Biotherapeutics Inc COMPOSITIONS AND METHODS OF INDUCING THE ACTIVATION OF UNREFERENCE MONOCYTIC DENDRITE CELLS
EP1840206A1 (en) * 2006-03-28 2007-10-03 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Compositions for the preparation of mature dendritic cells
CA2700573C (en) 2006-09-26 2016-11-22 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
WO2008039969A2 (en) 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
PL2328923T3 (pl) 2008-09-02 2016-06-30 Cedars Sinai Medical Center Epitopy CD133
PL2427485T3 (pl) 2009-05-07 2017-10-31 Immunocellular Therapeutics Ltd Epitopy CD133
CA2863653A1 (en) * 2012-02-02 2013-08-08 California Stem Cell, Inc. Pluripotent germ layer origin antigen presenting cancer vaccine
EP2857498B1 (en) * 2012-05-31 2018-04-25 JW Creagene Inc. Composition for maturing dendritic cells, and method for preparing antigen-specific dendritic cells using same
AU2020203845C1 (en) * 2012-09-06 2022-08-11 Orbis Health Solutions, Llc Tumor lysate loaded particles
US20140065173A1 (en) * 2012-09-06 2014-03-06 Orbis Health Solutions Llc Tumor lysate loaded particles
WO2014093454A1 (en) 2012-12-12 2014-06-19 Orbis Health Solutions, Llc Compositions and methods for tissue regeneration
WO2014127296A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd Cancer vaccines and vaccination methods
CN112891522A (zh) * 2013-09-05 2021-06-04 奥比思健康解决方案有限责任公司 装载了肿瘤裂解物的微粒
EP3113759B1 (en) 2014-03-05 2021-05-12 Orbis Health Solutions LLC Vaccine delivery systems using yeast cell wall particles
US9972054B1 (en) 2014-05-20 2018-05-15 State Farm Mutual Automobile Insurance Company Accident fault determination for autonomous vehicles
US11669090B2 (en) 2014-05-20 2023-06-06 State Farm Mutual Automobile Insurance Company Autonomous vehicle operation feature monitoring and evaluation of effectiveness
US10599155B1 (en) 2014-05-20 2020-03-24 State Farm Mutual Automobile Insurance Company Autonomous vehicle operation feature monitoring and evaluation of effectiveness
US10373259B1 (en) 2014-05-20 2019-08-06 State Farm Mutual Automobile Insurance Company Fully autonomous vehicle insurance pricing
US9792656B1 (en) 2014-05-20 2017-10-17 State Farm Mutual Automobile Insurance Company Fault determination with autonomous feature use monitoring
US9783159B1 (en) 2014-07-21 2017-10-10 State Farm Mutual Automobile Insurance Company Methods of theft prevention or mitigation
US10431018B1 (en) 2014-11-13 2019-10-01 State Farm Mutual Automobile Insurance Company Autonomous vehicle operating status assessment
EP3317402B1 (en) 2015-06-30 2024-02-14 Universidade Nova de Lisboa A viable cell population, method for production and uses thereof
MX2018000056A (es) * 2015-06-30 2018-05-28 Northwest Biotherapeutics Inc Celulas dendriticas optimamente activadas que inducen una respuesta inmunologica antitumoral mayor o mejorada.
US20210258486A1 (en) 2015-08-28 2021-08-19 State Farm Mutual Automobile Insurance Company Electric vehicle battery conservation
US11242051B1 (en) 2016-01-22 2022-02-08 State Farm Mutual Automobile Insurance Company Autonomous vehicle action communications
US10324463B1 (en) 2016-01-22 2019-06-18 State Farm Mutual Automobile Insurance Company Autonomous vehicle operation adjustment based upon route
US10134278B1 (en) 2016-01-22 2018-11-20 State Farm Mutual Automobile Insurance Company Autonomous vehicle application
US10386192B1 (en) 2016-01-22 2019-08-20 State Farm Mutual Automobile Insurance Company Autonomous vehicle routing
US11441916B1 (en) 2016-01-22 2022-09-13 State Farm Mutual Automobile Insurance Company Autonomous vehicle trip routing
US11719545B2 (en) 2016-01-22 2023-08-08 Hyundai Motor Company Autonomous vehicle component damage and salvage assessment
US10395332B1 (en) 2016-01-22 2019-08-27 State Farm Mutual Automobile Insurance Company Coordinated autonomous vehicle automatic area scanning
KR102038114B1 (ko) * 2016-02-26 2019-10-30 주식회사 엘지화학 광학 점착제용 (메타)아크릴레이트기 함유 벤조페논의 제조방법 및 광학 점착제 조성물
WO2018160666A1 (en) * 2017-02-28 2018-09-07 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Short-term activated dc1s and methods for their production and use
WO2019183924A1 (en) * 2018-03-30 2019-10-03 Syz Cell Therapy Co. Improved multiple antigen specific cell therapy methods
MX2022004186A (es) * 2019-10-07 2022-07-19 Northwest Biotherapeutics Inc Composiciones y métodos in vitro para potenciar la activación de células dendríticas y células t, y para inducir una respuesta inmune th-1.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US5366866A (en) * 1991-07-25 1994-11-22 Duke University Method of diagnosing ovarian and endometrial cancer with monoclonal antibodies OXA and OXB
US5227471A (en) * 1992-01-30 1993-07-13 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Monoclonal antibody PD41 that binds to a prostate mucin antigen that is expressed in human prostatic carcinoma
US5788963A (en) 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
BR9610802A (pt) * 1995-10-04 1999-07-13 Immunex Corp Método para melhoria da resposta imunológica método de preparo de células t de antígeno específico método para induzir tolerância de tecido de enxerto auxiliar de vacina meio de expansão e preparação de células dentríticas população de células dentríticas e respectivo método de preparo método para direcionar células-tronco hematopoiéticas ou células progenitoras a uma linhagem de células dentríticas
US7659119B2 (en) * 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
ATE428769T1 (de) * 1997-10-27 2009-05-15 Univ Rockefeller Methode und zusammensetzung zur herstellung von reifen dendritischen zellen
JP2000143534A (ja) * 1998-11-13 2000-05-23 Asahi Chem Ind Co Ltd 樹状細胞ワクチン及びその製造方法
JP2000279181A (ja) * 1999-04-01 2000-10-10 Japan Science & Technology Corp ヒト樹状細胞の発現遺伝子群
WO2001048154A1 (en) * 1999-12-28 2001-07-05 Toyoshima, Kumao Maturation-promoting agent for immature dendritic cells
US6247378B1 (en) * 2000-01-06 2001-06-19 Deere & Company Operator control device for an infinitely variable transmission
DK1292321T3 (da) * 2000-05-12 2012-01-30 Northwest Biotherapeutics Inc Fremgangsmåde til at forøge klasse 1 præsentation af exogene antigener gennem humane dendritiske celler
ES2254527T3 (es) * 2001-01-15 2006-06-16 I.D.M. Immuno-Designed Molecules Metodo para la preparacion de suspensiones de particulas submicronicas de agentes farmaceuticos.
WO2003010292A2 (en) * 2001-07-25 2003-02-06 Northwest Biotherapeutics, Inc. Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors

Similar Documents

Publication Publication Date Title
JP2011188872A5 (enExample)
JP5777956B2 (ja) 単球性樹状細胞およびt細胞にth−1応答をプライミングするための組成物および方法
Allavena et al. IL‐10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages
JP3631496B2 (ja) 樹状細胞刺激因子
EP2531216B1 (en) Icos critically regulates the expansion and function of inflammatory human th17 cells
JP2008515439A5 (enExample)
Hou et al. Host response to Sendai virus in mice lacking class II major histocompatibility complex glycoproteins
JP2014511704A5 (enExample)
US20010026937A1 (en) Monocyte-derived dendritic cell subsets
AU2003214566A1 (en) Functionalization of T cell derived vesicles and use thereof for the preparation of immunogenic pharmaceutical compositions
Zhang et al. Effective induction of immune tolerance by portal venous infusion with IL-10 gene-modified immature dendritic cells leading to prolongation of allograft survival
US20040022761A1 (en) Compositions and methods for producing antigen-presenting cells
US6596275B1 (en) Monocyte derived cells with immunosuppressive properties, process for their preparation and their uses in pharmaceutical compositions
KR102736008B1 (ko) 고순도 및 고효율의 자연살해세포 제조방법 및 이의 용도
JP2025504109A (ja) Ebv複合抗原、樹状細胞ワクチンおよびその使用
Citterio et al. Dendritic cells as natural adjuvants
CN113444688A (zh) 用于抗病毒抗肿瘤的人树突状细胞诱导方法及组合物
CN1282485C (zh) 负载凋亡的热休克肿瘤细胞的树突状细胞肿瘤疫苗及其制备方法与应用
Telemo et al. Antigen presentation and processing in the intestinal mucosa and lymphocyte homing
Onaitis et al. CD40 ligand is essential for generation of specific cytotoxic T cell responses in RNA-pulsed dendritic cell immunotherapy
EP1280889B1 (en) Compositions and methods for producing antigen-presenting cells
JP2002069001A (ja) 樹状細胞を主成分とする細胞ワクチン
US20090060946A1 (en) Activation of antigen-specific T cells by virus/antigen-treated dendritic cells
JP2002500872A5 (enExample)
US20080286315A1 (en) Methionine Enkephalin as an Adjuvant for Vaccine Immunizations